Valeant Announces First Quarter 2017 Results And Raises Full Year Adjusted EBITDA Guidance Range
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Valeant Pharma (VRX) Outperforms Amid Broad Weakness
May 11, 2017 9:54 AM EDTValeant Pharma (NYSE: VRX) Outperforms Amid Broad Weakness
... MoreValeant Pharma (VRX) Reports Q1 Adjusted EBITDA of $861M
May 9, 2017 7:05 AM EDTValeant Pharma (NYSE: VRX) reported GAAP Q1 EPS of $1.79, versus $1.08 reported last year. Revenue for the quarter came in at $2.11 billion, versus $2.37 billion reported last year.
Adjusted EBITDA (non-GAAP) of $861 Million2017 Guidance
2017 Full Year Adjusted EBITDA (non-GAAP) in the range of $3.60 - $3.75... More
